Compare ZKIN & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZKIN | AEON |
|---|---|---|
| Founded | 2015 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 8.0M |
| IPO Year | 2017 | N/A |
| Metric | ZKIN | AEON |
|---|---|---|
| Price | $2.02 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 14.8K | ★ 241.8K |
| Earning Date | 09-29-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $95,309,093.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.82 | $0.38 |
| 52 Week High | $6.30 | $64.80 |
| Indicator | ZKIN | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 37.17 | 42.13 |
| Support Level | $1.93 | $0.65 |
| Resistance Level | $2.39 | $0.83 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 8.82 | 22.45 |
ZK International Group Co Ltd is engaged in the manufacture and marketing of metal pipes. The company is specialized in producing double-press thin-walled stainless steel tubes and fittings, carbon steel tubes and fittings, single-press tubes and fittings, and stainless-steel strips. The products are used in restaurants, hotels, hospitals, firefighting, food, beverage, ships, engines, industrial seawater desalination and systems of direct-drinking water, cold /hot water supply, city water supply, and gas of large/middle scale construction projects.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.